A
Alexander S. Semikhin
Publications - 8
Citations - 2099
Alexander S. Semikhin is an academic researcher. The author has contributed to research in topics: Vaccination & Cellular immunity. The author has an hindex of 2, co-authored 5 publications receiving 1021 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Olga V. Zubkova,Amir I Tukhvatullin,Dmitry V. Shcheblyakov,Alina S. Dzharullaeva,Daria M. Grousova,Alina S. Erokhova,Anna V. Kovyrshina,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Nadezhda L. Lubenets,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Morozova Lf,Elena A Smolyarchuk,Evgeny V Kryukov,Vladimir F Babira,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +31 more
TL;DR: The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants and was safe and well tolerated.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
A. I. Tukhvatulin,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,T A Ozharovskaia,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Tatiana G. Zubkova,Konstantin A. Zakharov,Vasiliy B. Vasilyuk,Sergei V. Borisevich,B.S. Naroditsky,Denis Y. Logunov,Alexander L. Gintsburg +31 more
TL;DR: In this paper, a single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein -Sputnik Light was developed.
Posted ContentDOI
One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
Inna V. Dolzhikova,Vladimir A. Gushchin,Dmitry V. Shcheblyakov,Alexander Tsybin,Shchetinin Am,Andrey Pochtovyi,Andrey Komissarov,D. A. Kleymenov,Nadezhda P. Kuznetsova,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Alexander S. Semikhin,Elizaveta A. Tokarskaya,M M Shmarov,Natalia A. Nikitenko,Elena V. Shidlovskaya,Evgeniia N. Bykonia,E. P. Mazunina,Elizaveta V. Divisenko,Lyudmila Vasilchenko,Liubov I. Popova,Daria Danilenko,Dmitry Lioznov,Artem P. Tkachuk,Sergei V. Borisevich,Boris S. Naroditsky,Denis Y. Logunov,Alexander L. Gintsburg +35 more
TL;DR: In this article, the effectiveness of a single-dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow was investigated.
Journal ArticleDOI
[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].
E. I. Gusev,M Yu Martynov,N A Shamalov,Elena Yarovaya,M.P. Semenov,A M Semenov,A. Orlovsky,Vladimir A. Kutsenko,A. A. Nikonov,Sergey B. Aksentiev,D S Yunevich,Andrey Alasheev,O. V. Androfagina,V. V. Bobkov,K. V. Choroshavina,Vasiliy Gorbachev,I. V. Korobeynikov,I. V. Greshnova,A.V. Dobrovolskiy,U. A. Elemanov,N. V. Zhukovskaya,S. A. Zakharov,A. N. Chirkov,L. L. Korsunskaya,V.N. Nesterova,A. A. Nikonova,A A Nizov,A. I. Girivenko,É A Ponomarev,Daniil V. Popov,S.A. Pribylov,Alexander S. Semikhin,L. V. Timchenko,O. N. Jadan,Sergey Fedyanin,Zh Yu Chefranova,Yuriy Aleksandrovich Lykov,S. E. Chuprina,A.A. Vorobev,A. Archakov,S. S. Markin +40 more
TL;DR: It has been shown that a single bolus (within 10 s) administration of NS at a standard dose of 10 mg, regardless of body weight, allows to conduct fast, effective and safe thrombolytic therapy in patients with IS within 4.5 h after symptom onset.